Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness

July 27, 2012

WHAT: Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

The two analyses were presented at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C. The health benefits talk was presented by Beatriz Grinsztejn, M.D., HPTN site investigator for the Instituto de Pesquisa Clinica Evandro Chagas in Brazil. The cost-effectiveness talk was given by Kenneth A. Freedberg, M.D., MSc, an associate professor of medicine at Harvard Medical School and director of the Program in Epidemiology and Outcomes Research at the Harvard Medical School's Division of AIDS.

Initial results from the HPTN 052 study, announced in 2011, demonstrated that earlier use of by HIV-infected partnered with uninfected individuals (serodiscordant couples) reduced HIV transmission by 96 percent. In two years of follow-up analysis of 1,761 HIV-infected , researchers compared those who delayed antiretroviral treatment until their CD4+ T-cell counts were an average of 230 cells/ per cubic millimeter (mm³) with those who began antiretroviral treatment sooner (an average CD4 level of 440 cells/ mm³). The delayed group experienced a shorter time to a primary clinical event, including AIDS-defining disease and all types of tuberculosis. In total, there were 91 primary clinical events in the delayed treatment group versus 71 in the immediate group. This included 71 cases of AIDS-defining disease in the delayed treatment group versus 49 in the immediate group, and 34 cases of tuberculosis in the delayed group versus 17 in the immediate group. The trial provides evidence that earlier antiretroviral treatment among the HIV-infected provides significant health benefits.

In a separate modeling analysis designed to predict the clinical impact, costs and cost-effectiveness of the earlier antiretroviral treatment strategy, researchers compared the delayed treatment (CD4 counts of less than 250 cells/mm³) versus earlier treatment (350-550 cells/ mm³) data in South Africa and India. The two countries were selected to show how regional economic differences may or may not affect the conclusions. The researchers designated earlier treatment to be "very cost effective" if its cost-effectiveness ratio was less than one times per capita gross domestic product (GDP). Earlier treatment was deemed "cost effective" if its cost-effectiveness ratio was less than three times per capita GDP. The GDP was set at $8,100 for South Africa and $1,400 for India.

Using this model, they found that in both South Africa and India early ART increases patient survival, prevents costly —partially offsetting the costs of treatment—averts , and is cost-effective within a five-year span and very cost-effective over a lifetime.

Explore further: Expanded analysis of HPTN 052 study results show cost-effectiveness of early treatment of HIV

Related Stories

Expanded analysis of HPTN 052 study results show cost-effectiveness of early treatment of HIV

July 27, 2012
When the HIV Prevention Trials Network (HPTN) 052 investigators released their landmark study results last year showing that treatment can reduce HIV transmission by 96% in serodiscordant couples, questions were raised about ...

New HPTN 052 study results reveal additional benefits of early HIV treatment

July 26, 2012
Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes. Expanded analysis of HPTN 052 study data, presented today at ...

Hope for more options in couples where one partner is HIV positive

November 15, 2011
In sub-Saharan Africa, couples in long-term relationships where one partner is HIV-positive and the other is HIV-negative (HIV serodiscordant couples) could benefit from anti-AIDS drugs (antiretroviral therapy) given either ...

Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners

May 12, 2011
Men and women infected with HIV reduced the risk of transmitting the virus to their sexual partners by taking oral antiretroviral medicines when their immune systems were relatively healthy, according to findings from a large-scale ...

HIV prevention: Drugs even more effective than thought

July 18, 2011
Using HIV treatment drugs to reduce the risk of spreading the AIDS virus may be even more effective than thought, according to new analysis from a landmark trial presented here on Monday.

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.